Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19

BACKGROUND: Real-world data is currently limited on the association between oral antiviral therapy and healthcare system burden in patients with mild-to-moderate COVID-19. This study aims to evaluate the clinical and cost effectiveness of Molnupiravir and Nirmatrelvir-ritonavir use in reducing morta...

Descripción completa

Detalles Bibliográficos
Autores principales: Wai, Abraham Ka-Chung, Chan, Crystal Ying, Cheung, Annie Wai-Ling, Wang, Kailu, Chan, Sunny Ching-Long, Lee, Teddy Tai-Loy, Luk, Luke Yik-Fung, Yip, Edmond Tsz-Fung, Ho, Joshua Wing-Kei, Tsui, Omar Wai-Kiu, Cheung, Kelly Wing-Yin, Lee, Shiyeow, Tong, Chak-kwan, Yamamoto, Tafu, Rainer, Timothy Hudson, Wong, Eliza Lai-Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532222/
https://www.ncbi.nlm.nih.gov/pubmed/36212676
http://dx.doi.org/10.1016/j.lanwpc.2022.100602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532222/
https://www.ncbi.nlm.nih.gov/pubmed/36212676
http://dx.doi.org/10.1016/j.lanwpc.2022.100602

Ejemplares similares